O	O	0	8	Evidence	Evidence	B-NP	NN	O	0	ROOT	O
O	O	9	12	for	for	B-PP	IN	O	1	NMOD	O
O	O	13	14	a	a	B-NP	DT	O	8	NMOD	O
O	O	15	20	trans	trans	I-NP	AFX	O	8	NMOD	O
O	O	20	21	-	-	I-NP	HYPH	O	8	NMOD	O
O	O	21	27	acting	act	I-NP	VBG	O	8	NMOD	O
O	O	28	37	activator	activator	I-NP	NN	O	8	NMOD	O
O	O	38	46	function	function	I-NP	NN	O	2	PMOD	O
O	O	47	57	regulating	regulate	B-VP	VBG	O	8	NMOD	O
O	O	58	61	the	the	B-NP	DT	O	11	NMOD	O
O	O	62	72	expression	expression	I-NP	NN	O	9	OBJ	O
O	O	73	75	of	of	B-PP	IN	O	11	NMOD	O
O	O	76	79	the	the	B-NP	DT	O	16	NMOD	O
O	O	80	85	human	human	I-NP	JJ	B-protein	16	NMOD	B-protein
T1	B-Protein	86	89	CD5	CD5	I-NP	NN	I-protein	16	NMOD	I-protein
O	O	90	97	antigen	antigen	I-NP	NN	I-protein	12	PMOD	I-protein
O	O	97	98	.	.	O	.	O	1	P	O

O	O	100	112	Interspecies	Interspecies	B-NP	JJ	O	4	NMOD	O
O	O	113	120	somatic	somatic	I-NP	JJ	B-cell_line	4	NMOD	B-cell_line
O	O	121	125	cell	cell	I-NP	NN	I-cell_line	4	NMOD	I-cell_line
O	O	126	133	hybrids	hybrid	I-NP	NNS	I-cell_line	5	SUB	I-cell_line
O	O	134	138	were	be	B-VP	VBD	O	0	ROOT	O
O	O	139	148	generated	generate	I-VP	VBN	O	5	VC	O
O	O	149	151	by	by	B-PP	IN	O	6	VMOD	O
O	O	152	158	fusing	fuse	B-VP	VBG	O	7	PMOD	O
O	O	159	162	the	the	B-NP	DT	O	15	NMOD	O
O	O	163	168	mouse	mouse	I-NP	NN	B-cell_line	15	NMOD	B-cell_line
O	O	169	170	T	T	I-NP	NN	I-cell_line	15	NMOD	I-cell_line
O	O	170	171	-	-	B-NP	HYPH	I-cell_line	15	NMOD	I-cell_line
O	O	171	179	lymphoma	lymphoma	I-NP	NN	I-cell_line	15	NMOD	I-cell_line
O	O	180	184	cell	cell	I-NP	NN	I-cell_line	15	NMOD	I-cell_line
O	O	185	189	line	line	I-NP	NN	I-cell_line	17	NMOD	I-cell_line
O	O	189	190	,	,	O	,	O	17	P	O
O	O	191	197	BW5147	BW5147	B-NP	NN	B-cell_line	8	OBJ	B-cell_line
O	O	197	198	,	,	O	,	O	6	P	O
O	O	199	203	with	with	B-PP	IN	O	6	VMOD	O
O	O	204	210	normal	normal	B-NP	JJ	B-cell_type	23	NMOD	B-cell_type
O	O	211	216	human	human	I-NP	JJ	I-cell_type	23	NMOD	I-cell_type
O	O	217	218	T	T	I-NP	NN	I-cell_type	23	NMOD	I-cell_type
O	O	219	230	lymphocytes	lymphocyte	I-NP	NNS	I-cell_type	19	PMOD	I-cell_type
O	O	231	233	at	at	B-PP	IN	O	6	VMOD	O
O	O	234	243	different	different	B-NP	JJ	O	26	NMOD	O
O	O	244	250	stages	stage	I-NP	NNS	O	24	PMOD	O
O	O	251	253	of	of	B-PP	IN	O	26	NMOD	O
O	O	254	269	differentiation	differentiation	B-NP	NN	O	27	PMOD	O
O	O	269	270	.	.	O	.	O	5	P	O

O	O	271	281	Thymocytes	Thymocyte	B-NP	NNS	B-cell_type	14	NMOD	B-cell_type
O	O	281	282	,	,	O	,	O	14	P	O
O	O	283	292	activated	activate	B-NP	VBN	B-cell_type	6	NMOD	B-cell_type
O	O	293	303	peripheral	peripheral	I-NP	JJ	I-cell_type	6	NMOD	I-cell_type
O	O	304	305	T	T	I-NP	NN	I-cell_type	6	NMOD	I-cell_type
O	O	306	317	lymphocytes	lymphocyte	I-NP	NNS	I-cell_type	14	NMOD	I-cell_type
O	O	317	318	,	,	O	,	O	14	P	O
O	O	319	321	or	or	O	CC	O	14	NMOD	O
O	O	322	324	an	an	B-NP	DT	O	14	NMOD	O
O	O	325	334	activated	activate	I-NP	VBN	B-cell_line	14	NMOD	B-cell_line
O	O	335	336	T	T	I-NP	NN	I-cell_line	14	NMOD	I-cell_line
O	O	336	337	-	-	I-NP	HYPH	I-cell_line	14	NMOD	I-cell_line
O	O	337	341	cell	cell	I-NP	NN	I-cell_line	14	NMOD	I-cell_line
O	O	342	347	clone	clone	I-NP	NN	I-cell_line	15	SUB	I-cell_line
O	O	348	352	were	be	B-VP	VBD	O	0	ROOT	O
O	O	353	357	used	use	I-VP	VBN	O	15	VC	O
O	O	358	360	as	as	B-PP	IN	O	16	VMOD	O
O	O	361	366	human	human	B-NP	JJ	O	19	NMOD	O
O	O	367	375	partners	partner	I-NP	NNS	O	17	PMOD	O
O	O	375	376	,	,	O	,	O	16	P	O
O	O	377	389	respectively	respectively	B-ADVP	RB	O	16	VMOD	O
O	O	389	390	,	,	O	,	O	16	P	O
O	O	391	393	in	in	B-PP	IN	O	16	VMOD	O
O	O	394	399	three	three	B-NP	CD	O	26	NMOD	O
O	O	400	411	independent	independent	I-NP	JJ	O	26	NMOD	O
O	O	412	419	fusions	fusion	I-NP	NNS	O	23	PMOD	O
O	O	419	420	.	.	O	.	O	15	P	O

O	O	421	433	Irrespective	Irrespective	B-NP	JJ	O	16	SUB	O
O	O	434	436	of	of	B-PP	IN	O	1	NMOD	O
O	O	437	440	the	the	B-NP	DT	O	6	NMOD	O
O	O	441	446	human	human	I-NP	JJ	O	6	NMOD	O
O	O	447	451	cell	cell	I-NP	NN	O	6	NMOD	O
O	O	452	459	partner	partner	I-NP	NN	O	2	PMOD	O
O	O	460	464	used	use	B-VP	VBN	O	6	NMOD	O
O	O	465	468	for	for	B-PP	IN	O	7	VMOD	O
O	O	469	475	fusion	fusion	B-NP	NN	O	13	NMOD	O
O	O	475	476	,	,	O	,	O	13	P	O
O	O	477	478	a	a	B-NP	DT	O	13	NMOD	O
O	O	479	486	certain	certain	I-NP	JJ	O	13	NMOD	O
O	O	487	493	number	number	I-NP	NN	O	8	PMOD	O
O	O	494	496	of	of	B-PP	IN	O	13	NMOD	O
O	O	497	504	hybrids	hybrid	B-NP	NNS	B-cell_line	14	PMOD	B-cell_line
O	O	505	509	lost	lose	B-VP	VBD	O	0	ROOT	O
T2	B-Protein	510	513	CD5	CD5	B-NP	NN	B-protein	19	NMOD	B-protein
O	O	514	521	surface	surface	I-NP	NN	O	19	NMOD	O
O	O	522	532	expression	expression	I-NP	NN	O	16	OBJ	O
O	O	533	537	over	over	B-PP	IN	O	16	VMOD	O
O	O	538	539	a	a	B-NP	DT	O	22	NMOD	O
O	O	540	546	period	period	I-NP	NN	O	20	PMOD	O
O	O	547	549	of	of	B-PP	IN	O	22	NMOD	O
O	O	550	554	time	time	B-NP	NN	O	23	PMOD	O
O	O	555	557	in	in	B-PP	IN	O	22	NMOD	O
O	O	558	565	culture	culture	B-NP	NN	O	25	PMOD	O
O	O	565	566	.	.	O	.	O	16	P	O

O	O	567	575	Analysis	Analysis	B-NP	NN	O	8	SUB	O
O	O	576	578	at	at	B-PP	IN	O	1	NMOD	O
O	O	579	582	the	the	B-NP	DT	O	7	NMOD	O
O	O	583	592	phenotype	phenotype	I-NP	NN	O	7	NMOD	O
O	O	593	596	and	and	I-NP	CC	O	4	DEP	O
O	O	597	604	genetic	genetic	I-NP	JJ	O	4	DEP	O
O	O	605	610	level	level	I-NP	NN	O	2	PMOD	O
O	O	611	617	showed	show	B-VP	VBD	O	0	ROOT	O
O	O	618	622	that	that	B-SBAR	IN	O	8	VMOD	O
O	O	623	627	lack	lack	B-NP	NN	O	14	SUB	O
O	O	628	630	of	of	B-PP	IN	O	10	NMOD	O
T3	B-Protein	631	634	CD5	CD5	B-NP	NN	B-protein	13	NMOD	B-protein
O	O	635	645	expression	expression	I-NP	NN	O	11	PMOD	O
O	O	646	649	was	be	B-VP	VBD	O	9	SBAR	O
O	O	650	653	due	due	B-ADJP	JJ	O	14	PRD	O
O	O	654	661	neither	neither	B-PP	CC	O	15	PMOD	O
O	O	662	664	to	to	B-PP	TO	O	16	PMOD	O
O	O	665	676	segregation	segregation	B-NP	NN	O	17	PMOD	O
O	O	677	679	of	of	B-PP	IN	O	18	NMOD	O
O	O	680	685	human	human	B-NP	JJ	B-DNA	21	NMOD	B-DNA
O	O	686	694	autosome	autosome	I-NP	NN	I-DNA	19	PMOD	I-DNA
O	O	695	697	11	11	I-NP	CD	I-DNA	21	NMOD	I-DNA
O	O	697	698	,	,	O	,	O	21	P	O
O	O	699	701	on	on	B-PP	IN	O	21	NMOD	O
O	O	702	707	which	which	B-NP	WDT	O	24	PMOD	O
O	O	708	711	the	the	B-NP	DT	O	28	NMOD	O
T4	B-Protein	712	715	CD5	CD5	I-NP	NN	B-DNA	28	NMOD	B-DNA
O	O	716	720	gene	gene	I-NP	NN	I-DNA	29	SUB	I-DNA
O	O	721	724	has	have	B-VP	VBZ	O	24	SBAR	O
O	O	725	729	been	be	I-VP	VBN	O	29	VC	O
O	O	730	736	mapped	map	I-VP	VBN	O	30	VC	O
O	O	736	737	,	,	B-PP	,	O	21	P	O
O	O	738	741	nor	nor	I-PP	CC	O	16	PMOD	O
O	O	742	744	to	to	B-PP	TO	O	16	PMOD	O
O	O	745	753	deletion	deletion	B-NP	NN	O	34	PMOD	O
O	O	754	756	of	of	B-PP	IN	O	35	NMOD	O
O	O	757	760	the	the	B-NP	DT	O	40	NMOD	O
T5	B-Protein	761	764	CD5	CD5	I-NP	NN	B-DNA	40	NMOD	B-DNA
T8	B-Entity	765	775	structural	structural	I-NP	JJ	I-DNA	40	NMOD	I-DNA
T8	I-Entity	776	780	gene	gene	I-NP	NN	I-DNA	36	PMOD	I-DNA
O	O	780	781	.	.	O	.	O	8	P	O

O	O	782	793	Furthermore	Furthermore	B-ADVP	RB	O	8	VMOD	O
O	O	793	794	,	,	O	,	O	8	P	O
O	O	795	799	loss	loss	B-NP	NN	O	8	SUB	O
O	O	800	802	of	of	B-PP	IN	O	3	NMOD	O
T6	B-Protein	803	806	CD5	CD5	B-NP	NN	B-protein	7	NMOD	B-protein
O	O	807	814	surface	surface	I-NP	NN	O	7	NMOD	O
O	O	815	825	expression	expression	I-NP	NN	O	4	PMOD	O
O	O	826	836	correlated	correlate	B-VP	VBD	O	0	ROOT	O
O	O	837	841	with	with	B-PP	IN	O	8	VMOD	O
O	O	842	845	the	the	B-NP	DT	O	11	NMOD	O
O	O	846	853	absence	absence	I-NP	NN	O	9	PMOD	O
O	O	854	856	of	of	B-PP	IN	O	11	NMOD	O
O	O	857	865	specific	specific	B-NP	JJ	O	14	NMOD	O
O	O	866	870	mRNA	mRNA	I-NP	NN	B-RNA	12	PMOD	B-RNA
O	O	870	871	.	.	O	.	O	8	P	O

O	O	872	877	Since	Since	B-SBAR	IN	O	11	VMOD	O
O	O	878	883	these	these	B-NP	DT	O	3	NMOD	O
O	O	884	891	hybrids	hybrid	I-NP	NNS	O	5	SUB	O
O	O	892	906	preferentially	preferentially	B-ADVP	RB	O	5	VMOD	O
O	O	907	916	segregate	segregate	B-VP	VBP	O	1	SBAR	O
O	O	917	922	human	human	B-NP	JJ	B-DNA	7	NMOD	B-DNA
O	O	923	934	chromosomes	chromosome	I-NP	NNS	I-DNA	5	OBJ	I-DNA
O	O	934	935	,	,	O	,	O	11	P	O
O	O	936	941	these	these	B-NP	DT	O	10	NMOD	O
O	O	942	949	results	result	I-NP	NNS	O	11	SUB	O
O	O	950	958	indicate	indicate	B-VP	VBP	O	0	ROOT	O
O	O	959	962	the	the	B-NP	DT	O	13	NMOD	O
O	O	963	972	existence	existence	I-NP	NN	O	25	NMOD	O
O	O	973	975	of	of	B-PP	IN	O	13	NMOD	O
O	O	976	977	a	a	B-NP	DT	O	22	NMOD	O
T9	B-Entity	978	981	non	non	I-NP	AFX	B-DNA	22	NMOD	B-DNA
T9	I-Entity	981	982	-	-	I-NP	HYPH	I-DNA	22	NMOD	I-DNA
T9	I-Entity	982	990	syntenic	syntenic	I-NP	JJ	I-DNA	22	NMOD	I-DNA
T9	I-Entity	991	996	trans	trans	I-NP	AFX	I-DNA	22	NMOD	I-DNA
T9	I-Entity	996	997	-	-	I-NP	HYPH	I-DNA	22	NMOD	I-DNA
T9	I-Entity	997	1003	active	active	I-NP	JJ	I-DNA	22	NMOD	I-DNA
T9	I-Entity	1004	1009	locus	locus	I-NP	NN	I-DNA	14	PMOD	I-DNA
O	O	1009	1010	,	,	O	,	O	25	P	O
O	O	1011	1013	or	or	O	CC	O	25	NMOD	O
O	O	1014	1018	loci	locus	B-NP	NNS	O	11	OBJ	O
O	O	1018	1019	,	,	O	,	O	25	P	O
O	O	1020	1030	positively	positively	B-VP	RB	O	28	VMOD	O
O	O	1031	1042	controlling	control	I-VP	VBG	O	25	NMOD	O
O	O	1043	1046	the	the	B-NP	DT	O	30	NMOD	O
O	O	1047	1057	expression	expression	I-NP	NN	O	28	OBJ	O
O	O	1058	1060	of	of	B-PP	IN	O	30	NMOD	O
O	O	1061	1064	the	the	B-NP	DT	O	35	NMOD	O
O	O	1065	1070	human	human	I-NP	JJ	B-DNA	35	NMOD	B-DNA
T7	B-Protein	1071	1074	CD5	CD5	I-NP	NN	I-DNA	35	NMOD	I-DNA
O	O	1075	1079	gene	gene	I-NP	NN	I-DNA	31	PMOD	I-DNA
O	O	1079	1080	.	.	O	.	O	11	P	O
